Everything below concerns bremelanotide. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-04-18. Where a claim depends on a specific study, the study is described rather than over-claimed.
Reported pharmacodynamic effects include transient rises in blood pressure and heart rate, flushing, nausea and headache, appearing soon after dosing and resolving within hours. These responses were dose-related in early studies and shaped the label's cardiovascular cautions and blood pressure monitoring advice. Gastrointestinal upset is the most frequent reason cited for discontinuation in trials. Whether the vascular signal attenuates with repeated use is not settled. Central effects on desire are described as emerging over weeks rather than immediately, which points to a cumulative rather than acute process.
The compound binds several melanocortin receptor subtypes rather than a single target, with the strongest functional activity reported at MC4R and measurable activity at MC1R, MC3R and MC5R. MC4R populations are dense in hypothalamic nuclei that integrate energy balance, autonomic tone and reproductive behaviour, which is the anatomical basis for the proposed pro-desire effect. Because binding is not subtype-selective, pigmentary and vascular effects accompany central activity. Improving subtype selectivity is an active area of analogue design. Direct causal mapping from receptor occupancy to reported desire change in humans is not fully established.
After subcutaneous dosing, peak plasma concentrations appear within roughly one hour, and elimination is fast, with a half-life on the order of a few hours. Degradation is mainly proteolytic, and at least one circulating fragment retains receptor activity, so parent-drug levels alone do not describe total exposure. Clearance does not depend heavily on hepatic cytochrome enzymes, which lowers the likelihood of common metabolic interaction routes. Data in renal or hepatic impairment are limited. Repeated dosing does not appear to produce marked accumulation given the short half-life.
Receptor activation in hypothalamic and limbic circuits is the mechanism most often cited for the observed effects on sexual desire. Signalling through MC4R couples to Gs proteins and raises intracellular cyclic AMP, which in turn modulates dopaminergic tone in reward-related pathways. Because the peptide reaches the central nervous system after subcutaneous administration, peripheral vascular changes are regarded as secondary rather than primary. The precise neural circuits that translate receptor occupancy into behavioural change remain incompletely mapped, and published accounts describe the pathway in general terms rather than as a fully resolved sequence.
Development began with intranasal formulations investigated for erectile dysfunction, but blood pressure elevation limited that route and prompted a switch to subcutaneous delivery. Clinical testing then shifted toward hypoactive sexual desire disorder in premenopausal women, and a subcutaneous product received United States approval in 2019. Later trials examined other populations with mixed results, and questions about effect size, durability and patient selection remain open in the peer-reviewed literature. Research interest continues in parallel with the broader melanocortin field, where several synthetic analogues are studied together.
| Property | Value | Notes |
|---|---|---|
| Primary target | MC4R | Highest reported functional activity |
| Peak plasma time | About 1 hour | Subcutaneous administration |
| Elimination half-life | A few hours | Active fragment may extend effect |
| Main clearance route | Proteolytic degradation | Not cytochrome-dependent |
| Typical assay | LC-MS/MS | Plasma quantification |
Regulatory status varies by jurisdiction, where approved prescription products, compounded preparations and research-grade material are treated as distinct categories with different documentation requirements. Suppliers of research material commonly issue a certificate of analysis listing purity, identity and sometimes endotoxin content. Independent verification by a third-party laboratory is often recommended because self-reported figures are difficult to check. Literature discussions usually state the source, purity and storage conditions of the material used, since these details affect reproducibility. Analysts note that a reported purity figure does not by itself describe biological activity.
Lyophilised peptide is generally held below minus twenty degrees Celsius, protected from light and moisture, because hydrolysis and oxidation accumulate faster at ambient temperature. Once reconstituted, solutions are typically kept between two and eight degrees Celsius and used within a short window defined by the supplier. Repeated freeze-thaw cycles are avoided since they promote aggregation and loss of soluble material. Container material matters as well, because peptides adsorb to certain plastics and glass surfaces at low concentration. Stability figures supplied by a vendor apply only to the specific lot and buffer that were tested.
Approved use is narrow and jurisdiction-specific. In the United States, the injectable product is authorised for premenopausal women with acquired, generalised hypoactive sexual desire disorder, a diagnosis that requires documented distress. It is not approved for men, for postmenopausal women, or for use alongside hormonal contraceptives under the approved labelling. Outside regulated markets, the same peptide is frequently sold as a research chemical, where identity, purity, and sterility are not independently verified.
Bremelanotide is a synthetic cyclic heptapeptide developed as an analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation and appetite signalling. Its structure contains seven amino acid residues joined by a lactam bridge that closes the ring between two side chains. The molecular formula is C50H68N14O10 and the nominal molecular mass is near 1025 daltons. Much of the early laboratory literature refers to the same molecule by the development code PT-141.
He previously worked as an analyst with the International Crisis Group.; co-founder of J Street and has served on the organization's advisory council; also a founding board member of Molad: The Center for the Renewal of Israeli Democracy as well as the Diaspora Alliance; serves on board of New Israel Fund and as trustee of Rockefeller Brothers Fund; editor with Foreign Policy magazine as editor of their Middle East Channel He publishes and speaks widely on matters related to Israel and Palestine.; has appeared on and written for The Nation, The New York Times, Ha'aretz, the BBC, Al Jazeera, and CNN. Eylon Levy (born London, 1991) is an official Israeli government spokesman, serving since the start of Gaza war. He served previously as international media advisor to President Isaac Herzog, after a career as a television news anchor at i24News and IBA News. Levy's work has appeared in Newsweek, Jerusalem Post, Times of Israel, The Daily Caller, Arutz Sheva/Israel National News, Tablet Magazine, The Washington Post, The Guardian, and The Daily Telegraph. Martin Lewis (financial journalist) (born 9 May 1972) financial journalist and broadcaster, has worked for BBC, Channel 5 (British TV channel), ITV's This Morning (TV programme) and written for The Sunday Post, The Yorkshire Post, the Manchester Evening News, Express & Star, has been a columnist for The Sunday Times, News of the World, The Guardian and the Sunday Express. Tim Lott(born 23 January 1956); author and journalist for The Guardian.
== Activities == The CSCC monitors the quality of testing services and acts as technical experts to evaluate and select methods and instrumentation. They apply their clinical and technical knowledge to assist physicians in selecting and interpreting tests, as well as supporting the laboratory's research and teaching activities. The society also produces publications, including the scientific journal Clinical Biochemistry, a member newsletter CSCC News, and position papers on current issues such as cardiac troponin testing. Special interest groups have been developed to advance knowledge and produce solutions in Clinical Toxicology, Point-Of-Care Testing, Pediatric and Perinatal Biochemistry, Monoclonal Gammopathy, Autoverification of test results, and the Canadian Laboratory Initiative on Paediatric Reference Intervals - CALIPER.
=== Cannabinoid hyperemesis syndrome === Aprepitant has been identified as having strong potential in treating protracted vomiting episodes in individuals with cannabinoid hyperemesis syndrome. This syndrome is characterized by nausea, cyclical vomiting, and cramping abdominal pain resulting from prolonged, frequent cannabis use. Standard first-line antiemetics such as ondansetron and prochlorperazine are often ineffective in treating cannabinoid hyperemesis syndrome.
== Pharmacology == The pharmacodynamic profile of deupsilocin, including its interactions with serotonin receptors and its effects in animals, is similar to that of psilocin. As with psilocin, deupsilocin is a potent agonist of the serotonin 5-HT2A receptor and produces psychedelic-like effects in animals. However, it was developed to have improved pharmacokinetic properties compared to psilocybin, including reduced variability in circulating levels, a faster onset of action, and a shorter duration. In humans, deupsilocin has been reported to have 2.2-fold higher peak levels and 3.5-fold higher area-under-the-curve (AUC) levels than psilocybin at equivalent doses. It is said to have a rapid onset of less than 15 minutes and a duration of 4 to 6 hours.
Sources: en.wikipedia.org
Roderick S. Bucknell analysed four versions of the twelve nidanas, to explain the existence of various versions of the pratitya-samutpada sequence. The twelvefold version is the "standard version", in which vijnana refers to sensual consciousness. According to Bucknell, the "standard version" of the twelve nidanas developed out of an ancestor version, which in turn was derived two different versions that understand consciousness (vijñana) and name and form (namarupa) differently.
=== Anticancer therapeutics === Intracellular heat shock proteins are highly expressed in cancerous cells and are essential to the survival of these cell types due to presence of mutated and over-expressed oncogenes. Many HSPs can also promote invasiveness and metastasis formation in tumours, block apoptosis, or promote resistance to anti-cancer drugs. Hence small molecule inhibitors of HSPs, especially Hsp90 show promise as anticancer agents. The potent Hsp90 inhibitor 17-AAG was in clinical trials for the treatment of several types of cancer, but for various reasons unrelated to efficacy did not go on to Phase 3. HSPgp96 also shows promise as an anticancer treatment and is currently in clinical trials against non-small cell lung cancer.
Among the many varieties of microorganisms, relatively few cause disease in otherwise healthy individuals. Infectious disease results from the interplay between those few pathogens and the defenses of the hosts they infect. The appearance and severity of disease resulting from any pathogen depend upon the ability of that pathogen to damage the host as well as the ability of the host to resist the pathogen. However, a host's immune system can also cause damage to the host itself in an attempt to control the infection. Clinicians, therefore, classify infectious microorganisms or microbes according to the status of host defenses – either as primary pathogens or as opportunistic pathogens.
==== Donald Trump ==== In 1999, Hitchens wrote a profile of future president Donald Trump for The Sunday Herald. Trump had expressed interest in running in the 2000 presidential election as a candidate for the Reform Party. Of Trump, Hitchens said, "Because the man with many monikers in many ways embodies his country and because this election cycle is now so absurd, and so much up for grabs, it is unwise to exclude anything... The best guess has to be that here's a man who hates to be alone, who needs approval and reinforcement, who talks a better game than he plays, who is crude, hyperactive, emotional and optimistic." Hitchens had previously written that Trump demonstrated "nobody is more covetous and greedy than those who have far too much."
== Professional activities == After earning a Ph.D. degree in biochemistry, a medical degree, and completing a research postdoctoral fellowship at the University of Wisconsin–Madison, Holick completed a residency in medicine at the Massachusetts General Hospital in Boston. He has been practicing adult and pediatric endocrinology since 1978 and is professor of medicine, physiology and biophysics and director of the Bone Health Care Clinic and the Heliotherapy, Light, and Skin Research Center at Boston University Medical Center. It provides extensive evaluation and treatment programs for children and adults with various metabolic bone diseases including osteoporosis, osteomalacia, stress fractures in young athletic women and men, and minimum trauma and nontraumatic fractures in infants, children and adults with hypermobility syndromes, osteogenesis imperfecta, and Ehlers–Danlos syndrome. He has been director of the General Clinical Research Unit at Boston University for several years. Holick serves as chair of NASA's "Human Health Countermeasures Element" Standing Review Panel, chair of the Endocrine Practice Guidelines Committee for Vitamin D, and editor-in-chief of the medical journal Clinical Laboratory.
Sources: en.wikipedia.org
MC4R is regarded as the primary mediator on the basis of binding and functional assays. Other subtypes are also engaged, which helps explain flushing and related side effects. The step from receptor activation to reported desire change remains partly inferential.
Elimination is rapid, with a half-life of a few hours. An active fragment circulates after breakdown, so biological activity may outlast measurable parent drug. This is one reason single-timepoint measurements are limited.
Because breakdown is mainly proteolytic rather than cytochrome-dependent, classic metabolic interactions are less likely. Agents affecting blood pressure could still matter. Formal interaction studies are sparse.
The code designates bremelanotide, a cyclic heptapeptide melanocortin receptor agonist. It served as an internal research identifier before the compound entered formal clinical development. The code and the generic name refer to the same molecule.